DOCK8 and atopic eczema: Subsequently, the therapeutic benefits of dupilumab have been reported in controlling severe and extensive atopic dermatitis in patients with a range of primary immunodeficiencies, including STAT3 loss-of-function (LOF), autosomal recessive (AR) ZNF341 deficiency, DOCK8 mutations, autosomal dominant (AD) CARD11 LOF, X-linked agammaglobulinemia, Wiskott–Aldrich syndrome, ARPC1B deficiency, STAT6 gain-of-function (GOF), cytotoxic T lymphocyte antigen-4 insufficiency, and Netherton syndrome (2–6, 9–16).